Results 71 to 80 of about 779,655 (355)

Thin Patient, Fatty Liver [PDF]

Cureus, 2019
A 49-year-old lady with no past medical history presented with dysphagia and 40-pound weight loss, which occurred over eight months. On physical examination, she had proximal muscle weakness and crackles in basilar regions of the lungs. Labs were significant for low albumin, elevated transaminases, and high aldolase.
Mukthinuthalapati, V V Pavan Kedar, Attar, Bashar M, Abu Omar, Yazan, Nath, Vikas, Czapar, Carol, Gandhi, Seema R   +5 more
openaire   +2 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Combined evaluation of Fibrosis‐4 index and fatty liver for stratifying the risk for diabetes mellitus

Journal of Diabetes Investigation, 2022
Aims/Introduction To investigate whether the Fibrosis‐4 index can help stratify the risk of diabetes mellitus in patients with fatty liver disease.
Yasuhiko Todo, Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Toru Ishihara, Masumi Miyazaki, Akihito Shiomi, Hironobu Nakaguchi, Sayaka Kanzaki, Yasunori Yamamoto, Yohei Koizumi, Osamu Yoshida, Yoshio Tokumoto, Masashi Hirooka, Eiji Takeshita, Teru Kumagi, Yoshio Ikeda, Masanori Abe, Takeru Iwata, Yoichi Hiasa   +19 more
doaj   +1 more source

Metabolic interactions between vitamin A and conjugated linoleic acid [PDF]

, 2014
Lipid-soluble molecules share several aspects of their physiology due to their common adaptations to a hydrophilic environment, and may interact to regulate their action in a tissue-specific manner.
BANNI, SEBASTIANO, Belury, MA, CARTA, GIANFRANCA, Cordeddu, L, Giordano, E, MURRU, MARIA ELISABETTA, Ortiz, B, Quadro, L   +7 more
core   +2 more sources

The greater impact of PNPLA3 polymorphism on liver‐related events in Japanese non‐alcoholic fatty liver disease patients: A multicentre cohort study [PDF]

, 2023
Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Michihiro Iwaki, Hirokazu Takahashi, Miwa Kawanaka, Saiyu Tanaka, Yasuhide Mitsumoto, Masato Yoneda, Atsushi Nakajima, Ola Fjellström, Jenny E. Blau, Björn Carlsson, Takeshi Okanoue, Yoshito Itoh   +14 more
openalex   +1 more source

Nonalcoholic fatty liver disease [PDF]

Nature Reviews Disease Primers, 2015
Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are additional findings of portal and lobular inflammation and hepatocyte injury (which characterize nonalcoholic steatohepatitis (NASH)).
Brunt, Elizabeth M, Wong, Vincent W. S., Nobili, Valerio, Day, Christopher P., Sookoian, Silvia, Maher, Jacquelyn J., BUGIANESI, Elisabetta, Sirlin, Claude B., Neuschwander Tetri, Brent A., Rinella, Mary E.   +9 more
openaire   +6 more sources

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, EarlyView.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

Navigating hepatotoxicity of antibody-drug conjugates: from mechanistic insights to clinical and postmarketing evidence

Frontiers in Pharmacology
Antibody-drug conjugates (ADCs) are rapidly developing targeted cancer therapeutic agents that combine specific monoclonal antibodies with cytotoxic agents. Currently, 17 ADCs are approved for the global market for treating hematological and solid tumors
Yinuo Dong, Yang Zhi, Xiaoyun Li, Xiaoyun Li, Mingyang Ma, Minyan Ye, Sha Huang, Jieting Tang, Wei Zhong, Xiaohong Lei, Yimin Mao   +10 more
doaj   +1 more source

Correlation of Ultrasound Acoustic Radiation Force Impulse Elastography with Sonographic Severity Grading of Fatty Liver Disease [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Fatty liver is one of the commonly encountered incidental finding in routine ultrasonography practice. The fatty liver has been divided into three grades according to severity based on the degree of increased liver echotexture on ...
Varsha P Rangankar, Priya R Bhole, Sarang S Gosavi, Sarang R Rathod   +3 more
doaj   +1 more source

Animal models of NASH: getting both pathology and metabolic context right [PDF]

, 2015
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease.
Larter, Claire Z., Yeh, Matthew M.
core   +1 more source